Prothena Corporation plc Logo

Email this page: News Release

Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease

For security reasons, registration is required before you can use this feature.
* Indicates required field